Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Fate Therapeutics (FATE) Return on Equity (2016 - 2025)

Fate Therapeutics' Return on Equity history spans 13 years, with the latest figure at 0.62% for Q4 2025.

  • For Q4 2025, Return on Equity fell 5.0% year-over-year to 0.62%; the TTM value through Dec 2025 reached 0.62%, down 5.0%, while the annual FY2025 figure was 0.52%, 4.0% up from the prior year.
  • Return on Equity reached 0.62% in Q4 2025 per FATE's latest filing, up from 0.65% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.2% in Q2 2021 to a low of 0.65% in Q3 2025.
  • Average Return on Equity over 5 years is 0.47%, with a median of 0.48% recorded in 2024.
  • Peak YoY movement for Return on Equity: grew 25bps in 2021, then crashed -32bps in 2022.
  • A 5-year view of Return on Equity shows it stood at 0.31% in 2021, then plummeted by -97bps to 0.6% in 2022, then increased by 26bps to 0.45% in 2023, then dropped by -26bps to 0.57% in 2024, then decreased by -9bps to 0.62% in 2025.
  • Per Business Quant, the three most recent readings for FATE's Return on Equity are 0.62% (Q4 2025), 0.65% (Q3 2025), and 0.65% (Q2 2025).